Carboxylesterases in Drug Metabolism: Challenges and Opportunities
Carboxylesterases (CES) represent an important pathway of drug metabolism. However, the striking differences in terms of number of carboxylesterases and tissue distribution make interspecies extrapolation a challenge. Several factors affect biotransformation and efficacy of drugs that are metabolized by CES. CES-mediated clinical drug-drug interactions (DDI) should also be evaluated. The regulatory guidance recommends examining CES-mediated metabolism for drugs that do not undergo significant metabolism by CYP enzymes.
The presentation is a high-level overview of in vitro DDI and ADME studies required for drug development with a focus on study design and data interpretation, as well as red flags to look for in in vitro DDI study reports, including methods and conclusions drawn from the underlying data.
Date: Tuesday, March 12
Time: 1:30 PM - 2:30 PM
Room: 155 E
